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One hundred consecutive patients hospitalized in the
coronary care unit for unstable angina, excluding pa-
tients with Prinzmetal's variant angina, were random-
ized within 24 hours of admission to treatment with dil-
tiazem (50 patients) or propranolol (50 patients). Also
excluded were patients with previous coronary artery
bypass surgery and those receiving a beta-receptor
blocking agent at the time of hospital admission. Left
ventricular function and the extent of coronary artery
disease were similar in the two groups.
During the hospital stay, the number of chest pain
episodes decreased from a mean (± SD) of 0.75 ± 0.1
per patient per day to 0.26 ± 0.07 (p < 0.05) with
diltiazem and 0.29 ± 0.1 (p < 0.05) with propranolol
therapy. The circadian distribution of chest pain epi-
sodes was affected similarly. After 1 month, 14 of the
patients treated with diltiazem were symptom-free com-
Recognition of the role of coronary artery vasomotion in
ischemic heart disease has aided understanding of many of
the clinical aspects of angina (I). Thus, whereas a fixed
atherosclerotic obstruction appears to be the usual cause of
angina occurring during exercise, spasm or abnormal coro-
nary artery tone is believed to play a major role in rest
angina and, consequently, in unstable angina (1,2). Calcium
channel antagonists prevent coronary artery spasm, but beta-
receptor blocking drugs may aggravate it (3). For these
reasons, many studies (4-11) have been performed in recent
years using calcium channel antagonists in patients with
unstable angina. Although favorable clinical results were
generally reported, most studies dealt with a small number
of patients often treated with a combination of drugs, and
patients with ST segment depression and ST segment ele-
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pared with 13 treated with propranolol. At a mean fol-
low-up time of 5.1 months (range 1 to 15), death had
occurred in two patients in each group and myocardial
infarction in fivediltiazem- and four propranolol-treated
patients (differencenot significant). Coronary artery by-
pass surgery had been performed in 21 dihiazem- and
19 propranolol-treated patients (difference not signifi-
cant). Only 15 patients were symptom-free, 9 treated
with diltiazem and 6 with propranolol.
This similar result observed with the two forms of
treatment suggests that coronary artery spasm may not
be the main factor involved in unstable angina when
Prinzmetal's variant angina is excluded. It also suggests
that diltiazem can be used as an alternative to the usual
treatment with beta-receptor blocking drugs.
(J Am Coil CardioI1985;5:717-22)
vation during episodes of chest pain were included without
distinction.
The pathophysiology of these two electrocardiographic
manifestations of myocardial ischemia may, however, differ
and various mechanisms other than spasm may account for
unstable angina, such as progression in coronary artery dis-
ease (12), enhanced platelet reactivity (13,14) and prosta-
glandins (15). The purpose of our study was to compare the
clinical efficacy of a calcium channel antagonist (diltiazem)
and of a beta-receptor blocking drug (propranolol) in pa-
tients hospitalized with unstable angina, excluding patients
with the clinical syndrome of Prinzmetal's variant angina.
Methods
Study patients. All patients admitted to the coronary
care unit with the clinical diagnosis of unstable angina dur-
ing the study period were considered for the study. Unstable
angina was diagnosed whenever one of the following clinical
conditions was present (16): 1) crescendo angina defined by
the presence of chest pain with a recent increase in fre-
0735-1097/85/$3.30
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Patients
Table 1. Patient Selection and Exclusion Factors
quency, intensity and duration; 2) acute coronary insuffi-
ciency, that is, prolonged ischemic chest pain poorly re-
lieved by nitroglycerin and without electrocardiographic or
serum enzyme evidence of myocardial infarction; and 3)
spontaneous angina occurring 3 to 30 days after an acute
myocardial infarction. Inclusion in the study required doc-
umentation of transient ST segment or T wave changes
during an episode of chest pain . Prinzmetal's variant angina
was diagnosed when the electrocardiographic change con-
sisted of ST segment elevation; patients with this finding
were excluded from the study . The diagnosis of unstable
angina was confirmed independently by two cardiologists.
Ofa total of543 consecutive patients with this diagnosis.
100 signed the informed consent form and entered the trial.
The 443 other patients were excluded for the various reasons
defined in the original protocol (Table I). The most frequent
reasons for exclusion were age older than 65 years (60
patients), previous coronary artery bypass surgery (74 pa-
tients) , documented variant angina (76 patients) and treat-
ment with a beta-receptor blocking drug at the time of hos-
pital admission (IOI patients). This last exclusion criterion
was retained to avoid a possible rebound clinical effect when
stopping the medication . Other exclusion factors were par-
ticipation in another clinical trial , contraindication to one
of the study medications, coronary artery bypass surgery
already planned, patient or physician refusal and a follow-
up not possible for psychologic or physical reasons.
Patient management. All patients were hospitalized in
the coronary care unit. Bed rest, a mild sedative and iso-
sorbide dinitrate, 120 mg daily or as tolerated, were pre-
scribed . Aspirin was riot administered because no evidence
of a beneficial effect existed at the time of the study. An
electrocardiographic lead was continuously monitored. Se-
rial enzyme determination was performed to rule out myo-
cardial infarction. A 12 lead electrocardiographic tracing
was rapidly obtained on a three channel recorder whenever
the patient experienced an episode of chest pain, before the
No. %
administration of sublingual nitroglycerin. The episodes of
chest pain , their timing during the day and their duration
were closely monitored. The collection of data by the in-
vestigators was done without knowledge of the form of
treatment.
Treatment protocol. After the patient was judged to be
eligible for the study and written informed consent was
obtained, the patients were randomized to one of the two
study drugs. Randomization was done by a computer-gen-
erated hazard selection of drugs and equilibrated into blocks
of nine cases. The study drug was administered in single-
blind fashion within 12 to 24 hours after admission and
consisted of either 60 mg of diltiazem or 40 mg of pro-
pranolol. If this first dose was well tolerated, the dosage of
diltiazem was increased to 120 mg, three times daily, and
of propranolol to 80 mg, three times daily. The protocol
was then adjusted to the current management of unstable
angina patients. Blood pressure and heart rate were re-
corded . If the patient became free of pain, he or she was
progressively mobilized and coronary arteriography per-
formed after 3 to 6 days. If the clinical condition remained
unstable despite the high doses of the medication, the period
of bed rest was prolonged and an intravenous infusion of
nitroglycerin was started at a rate adjusted to the clinical
and hemodynamic response. Early coronary angiography
was considered if chest pain persisted despite this treatment.
At this stage, the option of a therapeutic trial with the other
study drug was given.
Coronary arteriography was performed in 93 patients;
in 7, it was not done because of the early occurrence of
myocardial infarction or death . A stenosis reducing the lu-
minal diameter by 70% or more was considered significant.
A left ventriculogram was obtained in the 30° right anterior
oblique projection in 76 patients; it was not obtained in 17
patients judged at higher risk by the cardiologist performing
the catheterization.
Persistent chest pain during hospitalization was an in-
dication for coronary artery bypass surgery whenever pos-
sible . The reason for bypass surgery in these patients was
classified as refractory angina . Surgery was also performed
on asymptomatic patients for elective reasons on the basis
of the severity of the coronary obstructive lesions . The med-
ication was withheld on the day of surgery and resumed 5
days after and continued during the follow-up period .
Follow-up. All patients were discharged taking the med-
ication to which they originally had been allocated, except
for the four patients who crossed over to treatment with the
other study drug . The study drug was stopped in three pa-
tients and the dose reduced in four others because of sus-
pected side effects; four of these patients were receiving
diltiazem and three were receiving propranolol. Follow-up
was obtained in a special unstable angina clinic I month
after randomization and every 3 months thereafter. A com-
19
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74
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46
35
31
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6
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100
Total admission s for unstable angina
No. randomized to treatment
Exclusion factors
Current treatment with beta-receptor blocking agents
Variant angina
Previous cardiac surgery
Age 65 years or older
Participation in another clinical trial
Contraindication to study medication
Scheduled corollary artery bypass surgery
Patient refusal
Follow-up impossible
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Table 2. Clinical and Angiographic Characteristics of 100
Randomized Patients
plete physical examination and a 12 lead electrocardiogram
were obtained at each visit. No patient was lost to follow-
up.
Statistical analysis. The clinical characteristics of the
patients at admission were compared by an unpaired Stu-
dent's t test for continuous variables and by a chi-square
test for discrete variables. An analysis of variance corrected
for repeated measures over time was used to compare the
hemodynamic response with both drugs during the hospital
stay. The clinical outcome with the two forms of treatments
was analyzed by the log-rank test.
Results
Clinical and angiographic characteristics. Fifty pa-
tients were randomized to diltiazem and 50 to propranolol.
Age, sex, family history of coronary artery disease, inci-
dence of previous myocardial infarction and diabetes, smok-
ing habits and cholesterol blood levels were similar in the
two treatment groups (Table 2). History of past hypertension
was more frequent in the diltiazem group (I8 versus 9 pa-
tients, p < 0.05). Although the same number of patients
had an abnormal basal electrocardiogram, the two groups
differed with regard to the clinical manifestation of unstable
angina. Crescendo angina was more frequent in the pro-
pranolol group (39 versus 29 patients, p < 0.05) and acute
coronary insufficiency was more frequent in the diltiazem
group (28 versus 13 patients, p < 0.05). The number of
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patients with spontaneous angina after myocardial infarction
was the same in both groups.
Coronary angiography showed absence of significant (70%
or greater) vessel stenosis in 9 of 93 patients; 36 patients
had one vessel disease, 34 two vessel disease and 14 three
vessel disease. An abnormal ventriculogram was found in
34 of the 76 patients who had the test. The extent of coronary
artery disease and left ventricular impairment were equally
distributed among the two treatment groups (Table 2).
Hemodynamic response to medication. Blood pres-
sure and heart rate were recorded four times daily during
hospitalization. Figure I displays the daily average of the
four recordings and also the rate-pressure product. At base-
line level, systolic blood pressure, heart rate and rate-pres-
sure product were very similar in the two treatment groups.
After treatment, all three hemodynamic variables became
significantly lower. The decrease was slightly greater with
propranolol, but the difference was not statistically signif-
icant compared with diltiazem.
First month follow-up. Before treatment, the mean
number (± standard deviation) of episodes of chest pain
per day was 0.75 ± 0.1 per patient. With propranolol, it
decreased to 0.26 ± 0.07 and with diltiazem to 0.29 ±
Figure 1. Hemodynamic responses to treatment. The four daily
recordings of heart rate (HR), systolic blood pressure (SYST BP)
and rate-pressure product (HR x SYST BP) were averaged to
give a value before treatment (day 0) and daily thereafter for the
first week of treatment. Significant reduction in the three variables
is observed with each drug compared with baseline level, but.the
difference between the two treatments is not significant (NS).
*p < 0.05 compared with baseline level.
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*p < 0.05. tThe angiogram was not done in seven patients because
of early myocardial infarction or death. ECG '" electrocardiogram; F '"
female; M '" male.
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Figure 2. Circadian distribution of episodes of angina . Before
treatment (B), the number of episodes of chest pain per patient
was minimal between midnight and 8 AM, but increased between
8 AM and 4 PM and again between 4 PM and midnight. Both
medications affected the circadian distribution in a similar pattern .
1 MONTH : DEATH OK ON Rx ANGINA CABS
0.09. The difference between baseline level and each of the
two forms of treatment was significant (p < 0.05) ; however,
no statistical difference existed between the two treatments .
The circadian distribution of episodes of chest pain was also
affected similarly (Fig. 2) . The incidence was minimal at
night and increased during the day to peak in the evening .
This curve was flattened by the two medications.
Figures 3 and 4 summari ze the clinical evolution during
hospitalization and during the fir st month follow-up for the
100 patients . Death occurred in two patients in each treat-
ment group; three patients taking diltiazem had a myocardial
infarction compared with two patients taking propranolol.
Coronary artery bypass surgery was performed in 15 patients
receiv ing diltiazem and 16 receiving propranolol; the in-
dication was persistent angina for , respectively, 6 and 4
patients and severity of the coronary artery lesion for 9 and
12 patients (difference not significant). Thirty-nine patients
Figure 4. Early clinical outcome of the 50 patients randomized
to propranolol therapy . Abbreviations as in Figure 3.
taking diltiazem and 40 taking propranolol became angina-
free during the hospital stay . Angina recurred in the early
post-hospital phase in 16 and 17 patient s, respectively. One
of the seven patients with persistent angina while taking
diltiazern was treated with propranolol and became symp-
tom-free . Three patients taking propranolol were crossed
over to diltiazem; two had a favorable result , but the other
patient died. Overall , after I month , 27 of the medically
treated patients were symptom-free (14 from the diltiazem
group and 13 from the propranolol group) .
Long-term follow-up. The clinical evolution remained
similar during the long-term foIlow-up period, which ex-
tended to a mean of 5.1 months (range I to IS) (Fig. 5) .
Myocardial infarction occurred in an additional four pa-
Figure 3. Early clinical outcome of the 50 patients randomized
to diltiazcm therapy (B). The numbers describe the total number
of patients in each subset. CABS = coronary artery bypass sur-
gery ; CCU = coronary care unit; MI = myocardial infarction.
Figure 5. Comparison of the long-term follow-up (mean 5.1 months)
of the 50 patients randomized to diltiazem therapy and of the 50
patients randomized to propranolol therapy . The clinical evolution
was very similar in the two groups. Abbreviation s as in Figure 3.
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tients, two in the diltiazem group and two in the propranolol
group . Nonscheduled coronary artery bypass surgery mo-
tivated by recurrence of angina was performed in six patient s
taking diltiazem and three patients taking propranolol. An-
gina disappeared in three patients receiving diltiazem and
reappeared in two patients receiving propranolol. Without
coronary artery bypass surgery , 15 of the 100 patients orig-
inally enrolled were symptom-free after a mean of 5.1 months,
9 in the diltiazem group and 6 in the propranolol group.
Discussion
In this clinical trial using at random a calcium channel
antagonist or a beta-receptor blocking drug for the man-
agement of unstable angina, very similar results were found
with the two forms of treatment. The reduction in the num-
ber of chest pain episodes, the occurrence of major events
(death and myocardial infarction) and the need for coronary
artery bypass surgery during hospitalization and follow-up
were the same with diltiazem and propranolol treatment.
Previous studies on calcium antagonists in unstable
angina. Most previous studies have suggested that a cal-
cium channel antagoni st could be a better choice for treating
unstable angina. However, significantly different protocol s
were used . All these studies (4- 11) enrolled patients with
ST segment elevation as well as patients with ST segment
depression during the episodes of chest pain , the proportion
of patients with ST segment elevation varying between 27
and 67%. In many of these studies (4,5,8), the beneficial
effect of the calcium channel antagonist was limited to the
subset of patients with ST segment elevation . In the study
of Gerstenblith et al. (8) , 138 patients treated with pro-
pranolol and nitrates received at random placebo or nifed-
ipine treatment. After 4 months of follow-up, significantly
fewer treatment failures defined by death, myocardial in-
farction or the need for coronary artery surgery had occurred
in the nifedipine group (30 of 68 patients taking nifedipine
compared with 43 of 70 patients taking placebo, p < 0 .03).
The difference favoring nifedipine was found exclusively
in patients with ST segment elevation; in patients with ST
segment depression, failure occurred in 21 of the 42 patients
receiving nifedipine and in 25 of the 43 receiving placebo .
Another important protocol difference is that the majority
of the studie s (6,7,9- 11) evaluated a combination of treat-
ment with a nitrate , a beta-receptor blocking agent and a
calcium channel antagonist versus a nitrate and a beta-re-
ceptor blocking drug. In many studies (5,6, 10), a calcium
channel antagonist was added to the usual treatment in those
patients unresponsive to the usual treatment during the first
few hours after admission. In the study by Gerstenblith et
al. (8) , all patients received propranolol. In the study by
Muller et al. (11), approximately half received propranolol
while the other half received either propranolol or nifedi-
pine . In this last study, nifedipine was found to be equivalent
to conventional therapy for controlling chest pain and pre-
venting myocardial infarction and death.
Study design. The patients included in our study may
not be representative of the entire cohort of patients with
the clinical syndrome of unstable angina . A selection was
made by excluding patients demonstrating ST segment el-
evation during the episode s of chest pain , representing 14%
of our consecutive series of patients hospitalized for unstable
angina . Transient ST segment elevation during chest pain
is the diagnostic criterion for Prinzmetal's variant angina
(17). Coronary artery vasomotion or spasm has been doc-
umented to be the causative factor for this syndrome (18,19),
whereas the exact mechanism for unstable angina has not
yet been elucidated (12-15). In addition, only one active
drug was given per patient to avoid a possible confounding
effect on the results of a mixed treatment with beneficial
effect of a calcium channel antagonist for coronary artery
spasm (20,21) and a deleterious effect of a beta-receptor
blocking drug (3,20,22). In our series , exclusion of patient s
already taking beta-receptor blocking drugs could have re-
duced the number of patient s with three vessel disease,
although the distribution of the severity of the disease rep-
resents the spectrum of coronary artery disease and is com-
parable with that of other series (12,23).
The design of our study , however, does not eliminate
the possibility of added benefit in some patients of the com-
bined treatment , nor does it document that treatment with
an active drug is superior to treatment with placebo since
the latter was not used. However, use of a beta-receptor
blocking drug with nitrates is now the standard therapy for
unstable angina and our result s suggest that diltiazem may
be as effective as propranolol. Use of a more aggressive
nitrate regimen titrated to the individual patient according
to tolerance or hemodynamic response could have signifi-
cantly altered our results, particularly of chest pain control
(24) .
Study results. The results do not allow extrapolation on
the mechanism of action of diltiazem. Heart rate, blood
pressure and the rate-pressure product (the external indexes
of myocardial oxygen consumption) were slightly less re-
duced than with propranolol , but the differences were not
significant. No attempt was made to coordinate the record-
ings of heart rate and blood pressure with the ingestion of
the drugs; they simply represent the average of the daily
routine recordings. The fact that both a calcium channel
antagonist and a beta-receptor blocking drug had similar
clinical efficacy may suggest that coronary artery spasm is
not the main factor involved in unstable angina when pa-
tients with ST segment elevation are excluded. The results .
of the Veterans Admini stration Cooperative Study (14)
showing a protective effect of aspirin against acute myo-
cardial infarction and death in patients with unstable angina
are consistent with this observation .
Although the patients were assigned to medication by
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randomization, differences in some baseline characteristics
were observed. Patients with a previous history of hyper-
tension were more numerous in the diltiazem group, al-
though blood pressure and heart rate were very similar in
patients in both groups at entry. A second difference be-
tween groups existed in the distribution of the type of an-
gina. More patients in the propranolol group had a crescendo
type of angina and more patients in the diltiazem group had
acute coronary insufficiency. Responses to treatment might
have been influenced by these differences since they may
reflect different pathophysiologic mechanisms. However,
previous myocardial infarction, the extent of coronary artery
disease and left ventricular function were similar in the two
groups, suggesting the absence of an important imbalance
between groups. Although the number of patients was rel-
atively large, a type II error cannot be ruled out considering
that the most serious events (death and myocardial infarc-
tion) were relatively infrequent; potentially important dif-
ferences could thus have been missed. However, the fact
that no favorable trend with one form of treatment compared
with the other was observed suggests that diltiazem may
represent a valuable alternative to beta-receptor blocking
agents in the treatment of unstable angina. This could be
particularly important if a contraindication to beta-receptor
blocking drugs exists or if vasospastic disease is suspected.
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